Hip fracture risks increase with short-term PPI use in patients with Alzheimer's disease
Short-term PPI use is correlated with a greater risk of hip fracture among Alzheimer's patients.
(HealthDay News) — Short-term proton pump inhibitor use, but not long-term or cumulative use, is associated with an increased risk of hip fracture among Alzheimer's patients, according to a study published online March 6 in Alimentary Pharmacology and Therapeutics.
Sanna Torvinen-Kiiskinen, from the University of Eastern Finland in Kuopio, and colleagues used national data from the Finnish MEDALZ dataset to identify 4818 community-dwelling individuals with Alzheimer's disease who experienced incident hip fracture (mean age, 84.1 years). There were 19,235 controls matched with the cases at the date of hip fracture.
The researchers found that long-term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. However, there was an increased risk associated with current proton pump inhibitor use (adjusted odds ratio [OR], 1.12). The risk was also increased with short-term current use of (less than one year; adjusted OR, 1.23).
"Our findings do not support previous assumptions that long-term proton pump inhibitor use would be associated with an increased risk of hip fractures," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
- Torvinen‐Kiiskinen S, Tolppanen AM, Koponen M, et al. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control. Aliment Pharmacol Ther. 2018 March 6. doi: 10.1111/apt.14589